Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years

Accepted for Publication: October 19, 2021.

Published Online: November 5, 2021. doi:10.1001/jama.2021.19885

Corresponding Author: Salomon M. Stemmer, MD, Davidoff Cancer Center, Rabin Medical Center, Belinson Hospital, Sackler Faculty of Medicine, Tel Aviv University, 39 Jabotinsky St, Petah Tikva 49100, Israel (salomon.stemmer@gmail.com).

Author Contributions: Dr S. M. Stemmer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Eliakim-Raz and Leibovici-Weisman contributed equally to this work.

Concept and design: Eliakim-Raz, Leibovici-Weisman, S. M. Stemmer.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: All authors.

Critical revision of the manuscript for important intellectual content: Eliakim-Raz, Leibovici-Weisman, A. Stemmer, S. M. Stemmer.

Statistical analysis: A. Stemmer, S. M. Stemmer.

Obtained funding: S. M. Stemmer.

Administrative, technical, or material support: Eliakim-Raz, Leibovici-Weisman, Ness, Awwad, Ghantous, S. M. Stemmer.

Supervision: Eliakim-Raz, Leibovici-Weisman, S. M. Stemmer.

Conflict of Interest Disclosures: Dr S. M. Stemmer reported receiving research grants (to his institution) from CAN-FITE, AstraZeneca, BioLineRX, BMS, Clovis Oncology, CTG Pharma, Exelixis, GEICAM, Halozyme, Incyte, Lilly, Moderna, Teva Pharmaceuticals, and Roche, and owns stocks and options in CTG Pharma, DocBoxMD, TyrNovo, VYPE, Cytora, and CAN-FITE. No other disclosures were reported.

Data Sharing Statement: The data sets generated during this study are available from the corresponding author on request.

Additional Contributions: We thank Avital Bareket-Samish, PhD, BioInsight Ltd, for medical editing support. She received financial compensation for her contribution.